Holen Sie sich die Stockscreener-App
14.89
1.65%
-0.25
Handel nachbörslich:
14.89
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us
Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha
HC Wainwright Issues Negative Estimate for CRVS Earnings - MarketBeat
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - moomoo.com
HC Wainwright Brokers Decrease Earnings Estimates for CRVS - MarketBeat
The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - moomoo.com
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha
Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat
State Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRVS SWOT Analysis: Financial Losses and Growth Potential Revealed in 10-Q Filing - GuruFocus
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... - Yahoo Finance
Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Corvus posts wider Q2 2026 loss as trials advance - Investing.com
Corvus Eczema Trial Is Expected to Enroll About 200 Patients - stocktitan.net
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corvus Pharmaceuticals 2Q 2026: Net income $(17.96)M, EPS $(0.19) — 10-Q Summary - TradingView
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Corvus Pharmaceuticals earnings up next as trial progress eyed By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... By GuruFocus - Investing.com Canada
82,890 Shares in Corvus Pharmaceuticals, Inc. $CRVS Acquired by Seven Fleet Capital Management LP - MarketBeat
Avidity Partners Management LP Invests $1.68 Million in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Vivo Capital LLC Has $41.05 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
ADAR1 Capital Management LLC Sells 377,974 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Corvus Pharmaceuticals Inc (CRVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BlackRock (CRVS holder) reports 7.5% beneficial stake in Corvus Pharmaceuticals - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:12.925|Chg%:-0.145 - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Commodore Capital LP Buys New Holdings in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals Inc (CRVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Institutional Confidence - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:13.070|Chg%:-0.610 - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:13.950|Chg%:+0.580 - TradingKey
TradingKey - TradingKey
Corvus Pharmaceuticals, Inc. Revenue Breakdown – BX:C17 - TradingView
Corvus Pharmaceuticals director Ian T. Clark resigns from board - Bitget
Corvus Pharmaceuticals Announces Board Leadership Transition - TipRanks
Corvus Pharmaceuticals (CRVS) Slips 2.9% as Stock Tests Support Near $13.35Negative Gamma - dars.gov.et
Corvus Pharmaceuticals (CRVS) Q1 2026 earnings summary - Quartr
Corvus Pharmaceuticals (CRVS) Proxy filing Summary - Quartr
CRVS News | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill
Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary - Quartr
Corvus Pharmaceuticals (CRVS) Rallies 2.11% to $15.49, Approaching Resistance at $16.26Option Strike Build - dars.gov.et
Corvus Pharmaceuticals (CRVS) Stock Analysis Report | Financials & Insights - Benzinga España
CRVS Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Offset Pipeline Focus as Shares Climb - po-news-eg.net
Corvus Pharmaceuticals (CRVS) Gains 1.42% as Biotech Momentum Lifts Speculative NamesDaily Profile - dars.gov.et
Corvus Pharmaceuticals (CRVS) Gains 3.18% as Biotech Sector Finds Its FootingNew Listing Stocks - dars.gov.et
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):